ZS Associates

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.

Michael Shaw, JD, and Sharon Suchotliff, MPH, from ZS, discuss why measuring impact through a patient-centric lens is a business imperative for life sciences companies. They explore key considerations for a key challenge when thinking about impact for patients in the real world- the compliant measurement of non-promotional activities, results from an early ZS proof of concept to determine Patient Outcomes Impact (POI™) metrics, and discuss what you can do today to advance POI™ at your organization.

Sharon Suchotliff, associate principal at ZS and lead for patient centricity, discusses why patient centricity has become a business imperative for life sciences companies. Sharon delves into the measurement of patient centricity, provides examples of how different companies have approached this and ZS’s approach for Patient Outcomes Impact (POI).

Patient centricity is an imperative focus for the advancement of life sciences businesses, and Sharon Suchotliff from ZS delves into this topic by sharing her keen insights.

Hear from ZS experts, Lisa Bance, PharmD, MBA, Irina Groysman, PharmD, and Laurent Malivert, PhD, on the impact Virtual Reality technologies are having in the healthcare space. Explore opportunities for how VR can be leveraged in shaping clinical trials and in how clinical development and operations leaders can not only navigate through disruption but thrive in an era of reduced physical access. Live: Thursday, October 8, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after airing until Oct. 8, 2021.